extended release metformin

Phase 3

extended release metformin is one of 16 therapeutic programs targeting Anatomic Stage I Breast Cancer AJCC v8. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Anatomic Stage I Breast Cancer AJCC V8Recruiting

Mild Cognitive ImpairmentActive, not recruiting

Anatomic Stage I Breast Cancer AJCC V8Phase 3

Recruiting

Mild Cognitive ImpairmentPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Anatomic Stage I Breast Cancer AJCC V8

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Glucophage

EMD Serono

Phase 3

1 3

Verzenio

Eli Lilly

Phase 2

2 4

Lupron

Sun Pharmaceutical Industries, Inc.

Phase 2

1 5

Rogaine

Pfizer

Phase 2

1 6

Zoladex

TTerSera Therapeutics LLC

Phase 2

1 7

Zoladex

TTerSera Therapeutics LLC

Phase 2

1 8

Inluriyo

Eli Lilly

Phase 2

1 9

Femara

Novartis

Phase 1

1 10

Fisetin

MMayo Clinic

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Erythroplakia

NCT05237960

Q2 2027

PreclinicalActive, not recruiting

Mild Cognitive Impairment

NCT04098666

Q2 2031

Phase 3Recruiting

Anatomic Stage I Breast Cancer AJCC V8

NCT06763328

Clinical

Trials by Indication[1]

Anatomic Stage I Breast Cancer AJCC v81 trial

Metformin (Dimethylbiguanide) and Insulin Resistance in Women Completing Neoadjuvant and/or Adjuvant Cytotoxic Treatment of Stage I-III Breast Cancer

Recruiting·CCity of Hope Medical Center·Phase 3·NCT06763328·80 enrolled

Erythroplakia1 trial

M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05237960·34 enrolled

Mild Cognitive Impairment1 trial

Metformin in Alzheimer's Dementia Prevention

Active, not recruiting·CColumbia University·Preclinical·NCT04098666·326 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for extended release metformin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for extended release metformin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Columbia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CColumbia University

extended release metformin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q2 2031

Trials by Indication[1]

Anatomic Stage I Breast Cancer AJCC v81 trial

Erythroplakia1 trial

Mild Cognitive Impairment1 trial

References

Drug Info

Quick Facts

Related News